Next 10 |
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”) announces that it has finalized certain details regarding the previously announced merger of equals transaction (the “ Tra...
2024-05-15 07:53:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips AEterna Zentaris (NASDAQ: AEZS ) just reported results for the first quarter of 2024. AEterna Zentaris reported earnings per share of -$4.74. This was below the analyst es...
2024-05-15 01:19:37 ET More on Aeterna Zentaris Financial information for Aeterna Zentaris Read the full article on Seeking Alpha For further details see: Aeterna Zentaris GAAP EPS of -$4.74
Company ended the quarter with $29.5 million in cash DETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third quarter of 2024 All-stock merger of equals transaction with Ceapro Inc. exp...
2024-05-03 09:02:04 ET Aeterna Zentaris Inc. (AEZS) announced stock split at a ratio of 1-for-4 on 2024-05-03 ... Full story available on KlickAnalytics.com
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna ") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approvin...
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 - All-stock merger of equals transaction with Ceapro, Inc. expected to close i...
TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that securityholders of both biopharmaceutical devel...
ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably managed.” ISS states in it...
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value proposition More information and materials available at www.AEZSmerger.com Shareholders with questions or who ...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”) announces that it has finalized certain details regarding the previously announced merger of equals transaction (the “ Tra...
Company ended the quarter with $29.5 million in cash DETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third quarter of 2024 All-stock merger of equals transaction with Ceapro Inc. exp...